Martin Williams, Caraway Therapeutics CEO
On a continued hunt for Parkinson's breakthroughs, AbbVie turns to a biotech in its portfolio
Two and a half years ago, AbbVie’s venture arm quietly co-led a $23 million Series A for Rheostat Therapeutics, mostly betting on the idea of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
